News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...
Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...
Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its ...
The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...
For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback